(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Sa'ar warns German delegation: 'A Palestinian state would be a Hamas terror state' - 25 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- 3Most loved Real time feature: Which Stage Do You Like
- 4Vote In favor of Your Number one Sort Of Blossoms
- 5France honors the victims of the Paris attacks' night of terror 10 years on
- Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Which '80s Film Actually Holds Up Today?
- 2 new malaria treatments announced as drug resistance grows
- Vote In favor of Your Favored Web-based Venture Stage
- Improving as a Cook: Culinary Experiences in the Kitchen
- Strengthening through Wellness: Individual Preparation Achievement
- 5 Must-Attempt Intriguing Dishes from Around the World
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
